A Prognostic Nomogram Based on Log Odds of Positive Lymph Nodes to Predict Overall Survival for Non-Metastatic Bladder Cancer Patients after Radical Cystectomy

Jingtian Yang 1,2,3,†, Huasheng Huang 4,†, Wenshuang Li 1,2,3, Shengming Ran 1,2,3, Jintao Hu 1,2,3, Yishan Zhang 1,2,3, Wenjie Li 1,2,3, Changhao Chen 1,2,3,* and Wang He 1,2,3,*

1 Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510289, China
2 Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510289, China
3 Guangdong Clinical Research Center for Urological Diseases, Guangzhou 510289, China
4 Department of Urology, Houjie Hospital of Dongguan, Dongguan 523945, China
* Correspondence: chenchh53@mail.sysu.edu.cn (C.C.); hewang525344@126.com (W.H.)
† These authors contributed equally to this work.

Abstract: (1) Purpose: The purpose of this study was to evaluate the prognostic capacity of the pathological N status (pN), lymph node ratio (LNR), and the log odds of positive lymph nodes (LODDS), and to build a prognostic nomogram to predict overall survival (OS) for bladder cancer patients treated by radical cystectomy. (2) Methods: The clinical and pathological characteristics of 10,938 patients with bladder cancer were identified from the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2017. The predictive capacity was assessed by univariate and multivariate Cox regression analyses, the area under the receiver operating characteristic curve (AUC), and C-index. Calibration curves, decision curve analysis (DCA), and risk-grouping were utilized to evaluate the predictive accuracy and discriminative ability of the nomogram. (3) Results: LODDS was an independent risk factor for bladder cancer (all \( p < 0.001 \)) and demonstrated the highest values of C-index and AUC. The values of AUCs in the training cohort were 0.747, 0.743, and 0.735 for predicting 1-, 3-, and 5-year OS, respectively. Calibration curves and DCA curves suggested the excellent clinical application value of our nomogram. (4) Conclusions: LODDS is a better predictive indicator for bladder cancer patients compared to pN and LNR. The LODDS-incorporated nomogram has excellent accuracy and promising clinical application value for non-metastatic bladder cancer after radical cystectomy.

Keywords: bladder cancer; radical cystectomy; nomogram; overall survival

1. Introduction

Bladder cancer (BCa) is the second most common urinary cancer worldwide [1]. For organ-confined BCa, radical cystectomy (RC) is still the most effective therapeutic procedure and recommended treatment [2,3]. Despite the rapid progress in surgical techniques in recent decades, the long-term prognosis of BCa patients after RC remains unsatisfactory among all BCa patients. A large single-center study of 1054 patients undergoing RC reported that the 5- and 10-year overall survival (OS) rates were 66% and 43% [4]. The 5-year recurrence-free and cancer-specific survival rates of 888 BCa patients who underwent RC were 58% and 66%, respectively, from a multicenter database [5]. Therefore, prognosis classification will facilitate the identification of high-risk postoperative patients who should receive additional adjuvant therapy.

The tumor, node, metastasis (TNM) classification is recommended to assess the prognosis of BCa and classify the extent of cancer dissemination [2]. For BCa patients, lymphatic metastasis is associated with a poor prognosis [6,7]. Nevertheless, the pathological N status
(pN) depends only on the area of the lymph nodes (LNs) and whether there are multiple lymph node metastases in the TNM system. With failure to remove sufficient lymph nodes, inaccurate staging and prognostic prediction can occur. The exact number of examined LNs (ELN) and positive LNs (PLN) are ignored, but may be essential clinicopathological information for prognosis prediction. Numerous studies conducted efforts to set up predictive models based on novel lymph node indicators. The lymph node ratio (LNR) and the log odds of positive lymph nodes (LODDS) have been proven to be efficient parameters to predict the prognosis of various cancers [8–11]. The former refers to the ratio of PLN to ELN, while the latter is the logarithm of the ratio of PLN to negative LNs. However, no predictive nomogram based on these two indicators has been set up to predict the OS of Bca patients after surgical resection. Accurate prediction of prognosis after surgery for Bca patients is essential for treatment strategy selection, disease staging, and health management.

This study tried to assess the predictive value of pN, LNR, and LODDS, and set up a nomogram for predicting the OS of nonmetastatic BCa patients after surgical resection.

2. Materials and Methods

2.1. Patient Selection

The Surveillance, Epidemiology, and End Results (SEER) database is a publicly available cancer data collaboration program collecting clinical and pathological information on patients with cancer. The data are available via SEER*Stat software (version 8.4.0). The clinical and pathological data of patients with BCa were extracted. The inclusion criteria included (1) patients diagnosed with BCa from 2004 to 2017; (2) patients who received RC. The exclusion criteria were as follows: (1) the exact numbers of ELN and PLN were unknown; (2) the clinical and pathological data (TNM stage/treatment/survival/grade/tumor size) were incomplete or unknown; (3) patients with metastatic BCa were excluded; (4) nonurothelial carcinoma was excluded.

2.2. Characteristics and Identification of Independent Prognostic Factors

The clinical and pathological characteristics included age, sex, race, primary site, pathological grade, neoadjuvant chemotherapy, tumor size, T stage, pN, ELN, PLN, LNR, and LODDS. For grade, ‘well differentiated’ and ‘moderately differentiated’ were defined as ‘low grade’, while ‘poorly differentiated’ and ‘undifferentiated; anaplastic’ were defined as ‘high grade’. LNR is the ratio of PLN to ELN. LODDS was computed by the following formula: \( \log \left( \frac{PLN+0.5}{ELN-PLN+0.5} \right) \). In addition, 0.5 was used to avoid an unlimited value [10,12]. LNR was divided into three subgroups, including LNR1 (<0.02), LNR2 (0.02–0.25), and LNR3 (>0.25). According to the cutoffs of −1.6 and −0.8, LODDS was divided into LODDS1 (<−1.6), LODDS2 (−1.6 ≥ LODDS ≤ −0.8), and LODDS3 (>−0.8).

The main endpoint of the current study was OS. A univariate and multivariate Cox regression model was performed to screen the independent prognostic factors. The predictive efficiency of pN, LNR, and LODDS was assessed using Kaplan–Meier curves, univariate and multivariate Cox models, the Harrell concordance index (C-index), and the area under the receiver operating characteristic curve (AUC).

2.3. Establishment, Validation, and Assessment of Prognostic Nomogram

The overall cohort was randomly divided into training and validation cohorts at the ratio of 7:3. Demographic, clinical, and pathological variables were compared between the two cohorts.

The significant variables from the univariate and multivariate Cox regression model were enrolled to establish the nomogram for predicting the OS of BCa patients after RC. The predictive capability of the nomogram was assessed by AUC and calibration curves. We divided participants in the overall cohort into high-risk and low-risk groups based on their total points calculated by our nomogram. The function ‘surv_cutpoint’ from R package ‘survminer’ was carried out to determine the optimal cut-point of total points. We
used the decision curve analysis (DCA) and Kaplan-Meier curve based on risk subgroups to evaluate the clinical applicability of the nomogram.

2.4. External Validation of the Nomogram

The external validation was performed using a cohort of patients from Sun Yat-sen Memorial Hospital. We reviewed all patients diagnosed with bladder cancer from January 2013 to April 2019 retrospectively. Finally, we included 239 patients who met the inclusion criteria and exclusion criteria for external validation. AUC and risk-grouping were used to verify the accuracy and discriminative ability of the nomogram.

2.5. Statistical Analysis

The data process flowchart is presented in Figure 1. All the categorical variables and the continuous variables were compared by chi-square test and Student’s t-test, respectively. Survival analysis was carried out via Kaplan–Meier curves with the Log-rank test. A $p$-value < 0.05 was considered to denote statistical significance. All the statistical tests were two-sided. All the statistical analyses were conducted with the statistical software R 4.1.3 (http://www.r-project.org; accessed on 17 April 2022).

Figure 1. Flow chart of the study. SEER, Surveillance, Epidemiology and End Results; pN: pathological N status; LNR: lymph node ratio; LODDS: log odds of positive lymph nodes; AUC: the area under the receiver operating characteristic curve; DCA: decision curve analysis.
3. Results
3.1. Clinical Characteristics

A total of 10938 bladder cancer patients were enrolled from the SEER database and randomly assigned to training (n = 7658) and validation cohorts (n = 3280) at a ratio of 7:3 randomly. Demographic, clinical, and pathological characteristics of the two cohorts were compared and are demonstrated in Table 1. In this study, 2354 patients received additional adjuvant chemotherapy. No significant difference was found in terms of demographic, clinical, and pathological characteristics between the two cohorts.

Table 1. Clinical and pathological characteristic.

| Variables | Overall Cohort | Training Cohort | Validation Cohort | p     |
|-----------|----------------|----------------|-------------------|-------|
|           | (n = 10,938)   | (n = 7658)     | (n = 3280)        |       |
| Age, n (%)|                |                |                   | 1.000 |
| <70       | 5889 (53.8%)   | 4123 (37.7%)   | 1766 (16.1%)      |       |
| >70       | 5049 (46.2%)   | 3535 (32.3%)   | 1514 (13.8%)      |       |
| Sex, n (%)|                |                |                   | 0.139 |
| Female    | 2658 (24.3%)   | 1830 (16.7%)   | 828 (7.6%)        |       |
| Male      | 8280 (75.7%)   | 5828 (53.3%)   | 2452 (22.4%)      |       |
| Race, n (%)|               |                |                   | 0.856 |
| White     | 9623 (88%)     | 6734 (61.6%)   | 2889 (26.4%)      |       |
| Others/Unknown | 1315 (12%) | 924 (8.4%) | 391 (3.6%) |       |
| Primary site, n (%) | | | | 0.362 |
| Trigone of bladder | 690 (6.3%) | 495 (4.5%) | 195 (1.8%) |       |
| Lateral wall of bladder | 1924 (17.6%) | 1365 (12.5%) | 559 (5.1%) |       |
| Posterior wall of bladder | 874 (8%) | 621 (5.7%) | 253 (2.3%) |       |
| Others/Unknown | 7450 (68.1%) | 5177 (47.3%) | 2273 (20.8%) |       |
| Grade, n (%) |                |                |                   | 0.428 |
| Low grade | 337 (3.1%)     | 243 (2.2%)     | 94 (0.9%)         |       |
| High grade | 10601 (96.9%)  | 7415 (67.8%)   | 3186 (29.1%)      |       |
| Neoadjuvant chemotherapy, n (%) | | | | 0.561 |
| Yes       | 1937 (17.7%)   | 1345 (12.3%)   | 592 (5.4%)        |       |
| No        | 9001 (82.3%)   | 6313 (57.7%)   | 2688 (24.6%)      |       |
| Tumor size, n (%) | | | | 0.967 |
| <40 mm    | 5364 (49%)     | 3754 (34.3%)   | 1610 (14.7%)      |       |
| ≥40 mm    | 5574 (51%)     | 3904 (35.7%)   | 1670 (15.3%)      |       |
| T, n (%)  |                |                |                   | 0.882 |
| T1, T2, T3 | 1176 (10.8%)  | 824 (7.5%)     | 352 (3.2%)        |       |
| T4        |                |                |                   |       |
| pN, n (%) |                |                |                   | 0.622 |
| pN0       | 8032 (73.4%)   | 5619 (51.4%)   | 2413 (22.1%)      |       |
| pN1       | 1188 (10.9%)   | 822 (7.5%)     | 366 (3.3%)        |       |
| pN2       | 1718 (15.7%)   | 1217 (11.1%)   | 501 (4.6%)        |       |
| Examined lymph nodes, mean ± SD | | | | 0.205 |
| Positive lymph nodes, mean ± SD | | | | 0.069 |
| LNR, n (%)|                |                |                   | 0.916 |
| LNR1      | 8066 (73.7%)   | 5648 (51.6%)   | 2188 (22.1%)      |       |
| LNR2      | 1892 (17.3%)   | 1329 (12.2%)   | 563 (5.1%)        |       |
| LNR3      | 980 (9%)       | 681 (6.2%)     | 299 (2.7%)        |       |
| LODDS, n (%) |            |                |                   | 0.629 |
| LODDS1    | 2884 (26.4%)   | 2005 (18.3%)   | 879 (8%)          |       |
| LODDS2    | 5779 (52.8%)   | 4009 (37.2%)   | 1710 (15.6%)      |       |
| LODDS3    | 2275 (20.8%)   | 1584 (14.5%)   | 691 (6.3%)        |       |

*pN: pathological N status; LNR: ratio of lymph node ratio; LODDS: log odds of positive lymph nodes; SD: standard deviation.

3.2. Survival Outcome and Independent Risk Factors

As shown in Figure 2, statistically significant differences in the Kaplan–Meier curves were observed among different pN, LNR, and LODDS subgroups (all p < 0.001). The outcomes of univariate and multivariate Cox regression analysis of OS are listed in Table 2.
Univariate analysis showed that age, race, primary site, neoadjuvant chemotherapy, tumor size, T stage, pN, LNR, and LODDS were related to OS ($p < 0.05$). All these significant variables were enrolled in the multivariate analysis. According to the results of multivariate analysis, finally, age, neoadjuvant chemotherapy, tumor size, T stage, LNR, and LODDS were the independent risk factors for OS among BCa patients after surgical resection (all $p < 0.05$). In the multivariate analysis, only LNR3 predicted decreased OS (LNR2 vs. LNR1, $p = 0.051$; LNR3 vs. LNR1, $p = 0.003$). However, LODDS2 and LODDS3 were both associated with poor OS compared with LODDS1 (both $p < 0.001$).

Figure 2. Kaplan–Meier curves of overall survival in the overall cohort according to pN (A), LNR (B), LODDS (C), and risk group (D). pN: pathological N status; LNR: lymph node ratio; LODDS: log odds of positive lymph nodes.
Table 2. Prognostic factors for overall survival of patients.

| Variable | Univariate Analysis | Multivariate Analysis |
|----------|---------------------|-----------------------|
|          | HR                  | 95% CI                | p Value | HR          | 95% CI      | p Value  |
| Age, n (%) |                     |                       |         |             |             |          |
| <70       | Reference            |                       |         | Reference   |             |          |
| ≥70       | 1.620               | 1.54–1.7              | <0.001  | 1.580       | 1.5–1.67    | <0.001   |
| Sex, n (%) |                     |                       |         |             |             |          |
| Male      | Reference            |                       |         | Reference   |             |          |
| Female    | 1.050               | 0.99–1.11             | 0.111   |             |             |          |
| Race, n (%) |                    |                       |         |             |             |          |
| White     | Reference            |                       |         | Reference   |             |          |
| Others/Unknown | 1.090   | 1.01–1.17           | 0.036   | 1.070       | 0.99–1.15   | 0.101    |
| Primary site, n (%) |                  |                       |         |             |             |          |
| Trigone of bladder | Reference  |                       |         | Reference   |             |          |
| Lateral wall of bladder | 0.810  | 0.72–0.91          | 0.001   | 0.940       | 0.84–1.06   | 0.339    |
| Posterior wall of bladder | 0.890  | 0.78–1.02          | 0.103   | 0.940       | 0.82–1.07   | 0.353    |
| Others/Unknown | 1.010  | 0.92–1.12          | 0.782   | 1.040       | 0.93–1.15   | 0.497    |
| Grade, n (%) |                     |                       |         |             |             |          |
| Low grade | Reference            |                       |         | Reference   |             |          |
| High grade | 1.080               | 0.94–1.25             | 0.283   | -           | -           | -        |
| Neoadjuvant chemotherapy, n (%) |          |                       |         |             |             |          |
| Yes       | Reference            |                       |         | Reference   |             |          |
| No        | 1.410               | 1.3–1.52              | <0.001  | 1.220       | 1.13–1.32   | <0.001   |
| Tumor size, n (%) |                |                       |         |             |             |          |
| <40 mm    | Reference            |                       |         | Reference   |             |          |
| ≥40 mm    | 1.300               | 1.24–1.37             | <0.001  | 1.170       | 1.11–1.23   | <0.001   |
| T, n (%)  |                     |                       |         |             |             |          |
| T1        | Reference            |                       |         | Reference   |             |          |
| T2        | 1.340               | 1.2–1.5               | <0.001  | 1.300       | 1.16–1.46   | <0.001   |
| T3        | 2.910               | 2.61–3.25             | <0.001  | 2.320       | 2.08–2.6    | <0.001   |
| T4        | 4.120               | 3.67–4.62             | <0.001  | 3.030       | 2.69–3.42   | <0.001   |
| pN, n (%) |                     |                       |         |             |             |          |
| pN0       | Reference            |                       |         | Reference   |             |          |
| pN1       | 1.910               | 1.77–2.06             | <0.001  | 0.800       | 0.48–1.34   | 0.401    |
| pN2       | 2.720               | 2.55–2.89             | <0.001  | 0.830       | 0.5–1.4    | 0.492    |
| LNR, n (%) |                     |                       |         |             |             |          |
| LNR1      | Reference            |                       |         | Reference   |             |          |
| LNR2      | 1.980               | 1.86–2.1              | <0.001  | 1.670       | 1–2.79     | 0.051    |
| LNR3      | 3.460               | 3.21–3.73             | <0.001  | 2.210       | 1.31–3.73   | 0.003    |
| LODDS, n (%) |                |                       |         |             |             |          |
| LODDS1    | Reference            |                       |         | Reference   |             |          |
| LODDS2    | 1.450               | 1.35–1.55             | <0.001  | 1.220       | 1.13–1.31   | <0.001   |
| LODDS3    | 3.080               | 2.86–3.32             | <0.001  | 1.580       | 1.43–1.74   | <0.001   |

HR: hazard ratio; CI: confidence interval; pN: pathological N status; LNR: lymph node ratio; LODDS: log odds of positive lymph nodes.

The predictive capacity of pN, LNR and LODDS is shown in Table 3. The C-index of values of pN, LNR, and LODDS were 0.601, 0.604, and 0.608, respectively. Moreover, the AUCs of LODDS (AUC = 0.633, 0.643, and 0.638) for 1-, 3-, and 5-year OS were higher than those for pN (AUC = 0.623, 0.641, and 0.632) and LNR (AUC = 0.628, 0.643, and 0.632).
Table 3. Evaluation of the prognostic value of pN, LNR, and LODDS.

|       | C-Index | AUC 1-Year OS | AUC 3-Year OS | AUC 5-Year OS |
|-------|---------|---------------|---------------|---------------|
| pN    | 0.601   | 0.623         | 0.641         | 0.632         |
| LNR   | 0.604   | 0.628         | 0.643         | 0.632         |
| LODDS | 0.608   | 0.633         | 0.643         | 0.638         |

AUC: the area under the receiver operating characteristic curve; pN: pathological N status; LNR: lymph node ratio; LODDS: log odds of positive lymph nodes; OS: overall survival.

3.3. Establishment, Validation, and Assessment of Prognostic Nomogram

According to the results of univariate and multivariate analysis, C-index, and AUC, LODDS was incorporated into the nomogram, rather than pN and LNR. In addition to LODDS, significant independent factors in Cox regression analyses, including age, neoadjuvant chemotherapy, tumor size, and T stage were incorporated into the prognostic nomogram (Figure 3). The total score was the sum of the corresponding scores of each variable and was used to calculate the probability of OS rates.

Figure 3. A nomogram to predict 1-, 3-, and 5-year overall survival for non-metastatic bladder cancer after surgical resection. LODDS: log odds of positive lymph nodes.
The prognostic value of the nomogram was estimated via operating characteristic curves (ROC) (Figure 4). In the training cohort, the AUCs of the 1-, 3-, and 5-year OS rates were 0.747, 0.743, and 0.735, while in the validation cohort the AUCs were 0.747, 0.740, and 0.737, respectively. The ROC curves show the excellent predictive accuracy of the nomogram. In the calibration curves, the good accordance between the predicted and actual OS rates was shown for the training cohort and validation cohort (Figure 5). The DCA curves demonstrated the optimal clinical application value (Figure 6). The optimal cut-point of total points for risk-grouping was 76.28. After subgroup analysis, we found that high-risk bladder cancer patients had a decreased OS ($p < 0.001$), which demonstrated the excellent discriminating power of our nomogram (Figure 2D).

Figure 4. Receiver operating characteristic curve of the nomogram in the training (A) and validation (B) cohorts.

Furthermore, the predictive performance of the nomogram was validated externally by the ROC curve and Kaplan–Meier curves of risk groups. In the external cohort, the AUCs for the 1-, 3-, and 5-year OS rates were 0.814, 0.847, and 0.783 (Figure 7A). After risk grouping, we found that high-risk bladder cancer patients had a decreased OS compared to low-risk patients ($p < 0.001$), indicating good discriminating power of our nomogram (Figure 7B).
The optimal cut-point of total points for risk-grouping was 76.28. After subgroup analysis, we found that high-risk bladder cancer patients had a decreased OS ($p < 0.001$), which demonstrated the excellent discriminating power of our nomogram (Figure 2D).

Furthermore, the predictive performance of the nomogram was validated externally by the ROC curve and Kaplan–Meier curves of risk groups. In the external cohort, the AUCs for the 1-, 3-, and 5-year OS rates were 0.814, 0.847, and 0.783 (Figure 7A). After risk grouping, we found that high-risk bladder cancer patients had a decreased OS compared to low-risk patients ($p < 0.001$), indicating good discriminating power of our nomogram (Figure 7B).

**Figure 5.** Calibration curves of the nomogram for predicting overall survival: (A) at 1 year in the training cohort; (B) at 3 years in the training cohort; (C) at 5 years in the training cohort; (D) at 1 year in the validation cohort; (E) at 3 years in the validation cohort; (F) at 5 years in the validation cohort. OS: overall survival.

**Figure 6.** Decision curve analysis for the nomogram in the training (A) and validation (B) cohorts.

**Figure 7.** Receiver operating characteristic curve (A) and Kaplan–Meier curves of risk group (B) of the external validation cohort.
In our research, we evaluated the predictive ability of pN, LNR, and LODDS, and then established a nomogram based on the most effective lymph node indicator of OS for BCa patients after surgical resection within a large cohort. Excellent discrimination and calibration were presented and validated in the prognostic model by the ROC curves and calibration curves. Subgroup Kaplan–Meier analysis according to risk group also showed that the nomogram can identify high-risk bladder cancer patients with poor prognostic outcomes after surgical resection.

Several studies have attempted to evaluate the prognostic ability of novel indicators, including LNR and LODDS. Analysis of data from two prestigious cancer centers showed that pN and LNR were significant predictors for disease-specific survival \( p < 0.1 \), but only LNR higher than 20% was associated with decreased disease-specific survival [13]. Comparable results were presented by Fleischmann et al., who analyzed a consecutive cohort of 507 patients with urothelial carcinoma of bladder cancer [14]. In the univariate analysis, different LNRs had a significant influence on recurrence-free survival \( p = 0.0034 \) and OS \( p = 0.0002 \) [14]. A meta-analysis with a total number of 3311 patients across 14 studies also reported similar results [15]. In addition to LNR, LODDS was considered to be a more accurate indicator for the lymph node category in various studies. A retrospective study had shown that LODDS was a superior predictive indicator for disease-free survival compared to pN and LNR in patients with rectal cancer [16]. Similar results and conclusions can be found in various studies with different cancers including lung squamous cell carcinoma [17], squamous cell carcinoma of the penis [18], colon cancer [19], endometrial carcinosarcoma [20], etc. For bladder cancer, Jin et al. assessed the predictive capacity of pN, LNR, and LODDS in patients with muscle-invasive urothelial carcinoma of bladder cancer [12]. They found that LODDS was better at predicting prognosis for muscle-invasive urothelial carcinoma of bladder cancer compared with pN and LNR [12]. However, the population of this study was limited to muscle-invasive bladder cancer patients, and histology was confined to transitional cell carcinoma. We compared the predictive ability of three lymph node indicators in non-metastatic bladder cancer patients and all pathological types.
were incorporated. In addition, a predictive nomogram for wider stage and pathological types was set up to predict OS for bladder cancer patients.

The nomogram incorporated several independent prognostic factors from univariate and multivariate analyses, including age, neoadjuvant chemotherapy, tumor size, and T stage. In previous studies, age and T stage have always been the independent risk factors for survival outcomes [21–23]. Meanwhile, tumor size has been considered as an independent risk factor of OS for patients after radical cystectomy in previous studies [24–26]. Moreover, mounting evidence has proven that neoadjuvant chemotherapy followed by radical cystectomy improves the survival outcome compared to radical cystectomy alone [27–29].

To our knowledge, for the first time, this study developed a nomogram incorporating LODDS and confirmed that LODDS is a valuable predictive factor for the overall survival of bladder cancer for the first time. Furthermore, the establishment of our prognostic model was based on a very large cohort from the SEER database, which provided large amounts of clinicopathological data with credibility. The accuracy and clinical application value of our prognostic model were demonstrated, and the clinicopathological variables incorporated in our nomogram can be readily obtained in clinical practice. Moreover, a visible nomogram can make it easier for clinicians to estimate 1-, 3-, and 5-year OS for BCa patients, which can assist in the development of individualized treatment strategies and health management. Moreover, the risk subgrouping based on the prognostic model allows clinicians to identify high-risk patients with worse prognoses and develop a more aggressive treatment plan.

We should point out several limitations of our study. It was a retrospective study, although the current research was based on a large cohort of the population. Further validation of our findings is recommended prospectively in a multi-center context. Moreover, the data regarding cancer specific survival were not analyzed or described in this study. In addition, some clinical information could not be extracted from the SEER database, such as the chemotherapy regimen and the position of positive lymph nodes. More valuable clinicopathological information should be collected to refine our prognostic model.

5. Conclusions

For postoperative patients with bladder cancer, LODDS is a valuable prognostic factor with an excellent predictive ability compared to pN and LNR. A prognostic nomogram based on a large cohort of the population was established, incorporating age, neoadjuvant chemotherapy, tumor size, T stage, and LODDS. This prognostic model may facilitate the prediction of prognosis and individual treatment strategy development for clinicians.

Author Contributions: J.Y. and H.H.: research ideas and drafting drafts; W.L. (Wenshuang Li): revising the data and statistical analysis; S.R. and J.H.: data extraction and revising the data; Y.Z.: review of the draft; W.L. (Wenjie Li): quality control; C.C. and W.H.: conception of research and quality control. All authors have read and agreed to the published version of the manuscript.

Funding: This study was funded by the National Natural Science Foundation of China (Grant No. 81972385, 82173266, 81825016, 81802530, 81830062, 81672395, 81871945, 81772719, 81772728, 2072639, 91740119, 81472381, 81802552); the National Key Research and Development Program of China (Grant No. 2018YFA0902803, 2017YFC1308600); the Key Areas Research and Development Program of Guangdong (Grant No. 2020A1515010815, 2018B010109006, 2017A020215072); the Science and Technology Planning Project of Guangdong Province (Grant No. 202002030388, 201803010049, 2017B020227007, 2017B04020097); Guangdong Clinical Research Center for Urological Diseases (Grant No. 2020B1111170006); the Yixian Youth project of Sun Yat-sen Memorial Hospital (Grant No. YXQH201812); Young Teacher Training Funding of Sun Yat-sen University (Grant No. 19ykzd21, 19ykpy121); the Science and Technology Program of Guangzhou, China (Grant No.201904010004); and the Natural Science Foundation of Guangdong Province, China (Grant No.2018A030313545).

Institutional Review Board Statement: Ethical approval was not needed as SEER is a de-identified, publicly available cancer database.

Informed Consent Statement: Informed consent was waived as SEER is a de-identified, publicly available cancer database.
Data Availability Statement: Publicly available datasets were analyzed in this study. These data can be found here: https://seer.Cancer.gov/ (accessed on 19 February 2022).

Conflicts of Interest: The authors have no conflict of interest.

References
1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin. 2021, 71, 209–249. [CrossRef] [PubMed]
2. Babjuk, M.; Burger, M.; Capoun, O.; Cohen, D.; Compérat, E.M.; Dominguez Escrig, J.L.; Gontero, P.; Liedberg, F.; Masson-Lecomte, A.; Mostafid, A.H.; et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur. Urol. 2022, 81, 75–94. [CrossRef] [PubMed]
3. Witjes, J.A.; Bruins, H.M.; Cathomas, R.; Compérat, E.M.; Cowan, N.C.; Gakis, G.; Hernández, V.; Espinós, E.L.; Lorch, A.; Neuzillet, Y.; et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur. Urol. 2021, 79, 82–104. [CrossRef] [PubMed]
4. Stein, J.P.; Lieskovsky, G.; Cote, R.; Groshen, S.; Feng, A.C.; Boyd, S.; Skinner, E.; Bochner, B.; Thangathurai, D.; Mikhail, M.; et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1054 patients. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2001, 19, 666–675. [CrossRef] [PubMed]
5. Shariat, S.F.; Karakiewicz, P.I.; Palapattu, G.S.; Lotan, Y.; Rogers, C.G.; Amiel, G.E.; Vazina, A.; Gupta, A.; Bastian, P.J.; Sagalowsky, A.I.; et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: A contemporary series from the Bladder Cancer Research Consortium. J. Urol. 2006, 176 Pt 1, 2414–2422. [CrossRef] [PubMed]
6. May, M.; Herrmann, E.; Bolenz, C.; Tiemann, A.; Brookman-May, S.; Fritsche, H.M.; Burger, M.; Buchner, A.; Gratzke, C.; Wülfing, C.; et al. Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy. Eur. Urol. 2011, 59, 712–718. [CrossRef]
7. Shariat, S.F.; Ehdaiie, B.; Rink, M.; Cha, E.K.; Svatek, R.S.; Chromekti, T.F.; Fajkovic, H.; Novara, G.; David, S.G.; Daneshmand, S.; et al. Clinical nodal staging scores for bladder cancer: A proposal for preoperative risk assessment. Eur. Urol. 2012, 61, 237–242. [CrossRef]
8. Zhao, E.; Zhou, C.; Chen, S. Prognostic nomogram based on log odds of positive lymph nodes for gastric carcinoma patients after surgical resection. Future Oncol. (Lond. Engl.) 2019, 15, 4207–4222. [CrossRef]
9. Li, R.; Lu, Z.; Sun, Z.; Shi, X.; Li, Z.; Shao, W.; Zheng, Y.; Song, J. A Nomogram Based on the Log Odds of Positive Lymph Nodes Predicts the Prognosis of Patients With Distal Cholangiocarcinoma After Surgery. Front. Surg. 2021, 8, 757552. [CrossRef]
10. Zhou, W.; Huang, C.; Yuan, N. Prognostic nomograms based on log odds of positive lymph nodes for patients with renal cell carcinoma: A retrospective cohort study. Int. J. Surg. (Lond. Engl.) 2018, 60, 28–40. [CrossRef]
11. Yamashita, K.; Hosoda, K.; Ema, A.; Watanabe, M. Lymph node ratio as a novel and simple prognostic factor in advanced gastric cancer. Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol. 2016, 42, 1253–1260. [CrossRef] [PubMed]
12. Jin, S.; Wang, B.; Zhu, Y.; Dai, W.; Xu, P.; Yang, C.; Shen, Y.; Ye, D. Log Odds Could Better Predict Survival in Muscle-Invasive Bladder Cancer Patients Compared with nN and Lymph Node Ratio. J. Cancer 2019, 10, 249–256. [CrossRef] [PubMed]
13. Kassouf, W.; Agarwal, P.K.; Herr, H.W.; Munsell, M.F.; Spiess, P.E.; Brown, G.A.; Pisters, L.; Grossman, H.B.; Dinney, C.P.; Kamat, A.M. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: Analysis of pooled data from MDACC and MSKCC. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2008, 26, 121–126. [CrossRef]
14. Fleischmann, A.; Thalmann, G.N.; Markwalder, R.; Studer, U.E. Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2005, 23, 2358–2365. [CrossRef]
15. Ku, J.H.; Kang, M.; Kim, H.S.; Jeong, C.W.; Kwak, C.; Kim, H.H. Lymph node density as a prognostic variable in node-positive bladder cancer: A meta-analysis. BMC Cancer 2015, 15, 447. [CrossRef]
16. Xu, T.; Zhang, L.; Yu, L.; Zhu, Y.; Fang, H.; Chen, B.; Zhang, H. Log odds of positive lymph nodes is an excellent prognostic factor for patients with rectal cancer after neoadjuvant chemoradiotherapy. Ann. Transl. Med. 2021, 9, 637. [CrossRef] [PubMed]
17. Yu, Y.; Zhang, P.; Yao, R.; Wang, J.; Wang, P.; Xue, X.; Xiao, J.; Wang, Z. Prognostic value of log odds of positive lymph nodes in node-positive lung squamous cell carcinoma patients after surgery: A SEER population-based study. Transl. Lung Cancer Res. 2020, 9, 1285–1301. [CrossRef] [PubMed]
18. Patel, K.N.; Salunke, A.; Bhatt, S.; Sharma, M.; Jain, A.; Puj, K.; Rathod, P.; Warikoo, V.; Pandya, S.J. Log ODDS (LODDS) of positive lymph nodes as a predictor of overall survival in squamous cell carcinoma of the penis. J. Surg. Oncol. 2021, 123, 1836–1844. [CrossRef]
19. Persiani, R.; Cananzi, F.C.; Biondi, A.; Paliani, G.; Tufo, A.; Ferrara, F.; Vigorita, V.; D’Ugo, D. Log odds of positive lymph nodes in colon cancer: A meaningful ratio-based lymph node classification system. World J. Surg. 2012, 36, 667–674. [CrossRef]
20. Gao, L.; Lu, J.; Luo, X.; Zhang, D.; Jiang, G.; Zhang, X.; Gao, X.; Zheng, S.; Wang, X.; Shen, Y. Nomogram to predict overall survival based on the log odds of positive lymph nodes for patients with endometrial carcinosarcoma after surgery. BMC Cancer 2021, 21 Pt 1, 1149. [CrossRef]
21. Karakiewicz, P.I.; Shariat, S.F.; Palapattu, G.S.; Gilad, A.E.; Lotan, Y.; Rogers, C.G.; Vazina, A.; Gupta, A.; Bastian, P.J.; Perrotte, P.; et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. *J. Urol.* 2006, 176, 1354–1361. [CrossRef]

22. Shariat, S.F.; Karakiewicz, P.I.; Palapattu, G.S.; Amiel, G.E.; Lotan, Y.; Rogers, C.G.; Vazina, A.; Bastian, P.J.; Gupta, A.; Sagalowsky, A.I.; et al. Nomograms provide improved accuracy for predicting survival after radical cystectomy. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* 2006, 12, 6663–6676. [CrossRef] [PubMed]

23. Wang, J.; Wu, Y.; He, W.; Yang, B.; Gou, X. Nomogram for predicting overall survival of patients with bladder cancer: A population-based study. *Int. J. Biol. Markers* 2020, 35, 29–39. [CrossRef] [PubMed]

24. Yang, Z.; Bai, Y.; Liu, M.; Hu, X.; Han, P. Development and validation of a prognostic nomogram for predicting cancer-specific survival after radical cystectomy in patients with bladder cancer: A population-based study. *Cancer Med.* 2020, 9, 9303–9314. [CrossRef] [PubMed]

25. Xie, H.Y.; Zhu, Y.; Yao, X.D.; Zhang, S.L.; Dai, B.; Zhang, H.L.; Shen, Y.J.; Wang, C.F.; Zhang, H.Z.; Ye, D.W. Development of a nomogram to predict non-organ-confined bladder urothelial cancer before radical cystectomy. *Int. Urol. Nephrol.* 2012, 44, 1711–1719. [CrossRef]

26. Soria, F.; Pisano, F.; Gontero, P.; Palou, J.; Joniau, S.; Serretta, V.; Larré, S.; Di Stasi, S.; van Rhijn, B.; Witjes, J.A.; et al. Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy. *World J. Urol.* 2018, 36, 1775–1781. [CrossRef]

27. Kitamura, H.; Tsukamoto, T.; Shibata, T.; Masumori, N.; Fujimoto, H.; Hirao, Y.; Fujimoto, K.; Kitamura, Y.; Tomita, Y.; Tobisu, K.; et al. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209. *Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.* 2014, 25, 1192–1198. [CrossRef]

28. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration; Vale, C. Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis. *Lancet ( Lond. Engl.)* 2003, 361, 1927–1934. [CrossRef]

29. Griffiths, G.; Hall, R.; Sylvester, R.; Raghavan, D.; Parmar, M.K. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 trial. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* 2011, 29, 2171–2177. [CrossRef]